1998
DOI: 10.1007/s004310050855
|View full text |Cite
|
Sign up to set email alerts
|

Chronic relapsing thrombotic thrombocytopenic purpura: three case reports and update of the pathogenesis and therapeutic modalities

Abstract: Chronic relapsing thrombotic thrombocytopenic purpura (CRTTP) is the rarest type of TTP, usually presenting in childhood. The aetiology is still not fully explained. The disorder is associated with the presence in plasma of unusually large von Willebrand factor (UlvWF) multimers that are especially prominent between episodes. CRTTP can be prevented by periodic plasma transfusions. We report three children with congenital CRTTP who have been successfully treated and maintained in prolonged remission by the prop… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
4
0
1

Year Published

1999
1999
2006
2006

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 10 publications
(5 citation statements)
references
References 27 publications
0
4
0
1
Order By: Relevance
“…Regular infusions of FFP in patients with hereditary de®ciency of vWFcleaving protease may prevent further attacks of the disease. Although the biological half-life of the protease is about 2 to 4 days [12], prophylactic plasma therapy at intervals of 2 to 4 weeks appears to prevent relapses of TTP [18,20]. Maes et al [20] reported three children with CRTTP who were treated with regular FFP infusions every 2 weeks.…”
Section: Discussionmentioning
confidence: 99%
See 3 more Smart Citations
“…Regular infusions of FFP in patients with hereditary de®ciency of vWFcleaving protease may prevent further attacks of the disease. Although the biological half-life of the protease is about 2 to 4 days [12], prophylactic plasma therapy at intervals of 2 to 4 weeks appears to prevent relapses of TTP [18,20]. Maes et al [20] reported three children with CRTTP who were treated with regular FFP infusions every 2 weeks.…”
Section: Discussionmentioning
confidence: 99%
“…Although the biological half-life of the protease is about 2 to 4 days [12], prophylactic plasma therapy at intervals of 2 to 4 weeks appears to prevent relapses of TTP [18,20]. Maes et al [20] reported three children with CRTTP who were treated with regular FFP infusions every 2 weeks. Using this schedule, the patients were maintained in remission for over 3 years [20].…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…1). Anhand des Auftretens der einzelnen Krankheitsepisoden können des Weiteren akute einzelne Episoden von intermittierend rezidivierenden oder auch chronisch rezidivierenden Formen unterschieden werden (20).…”
Section: Fallberichtunclassified